A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: A Pediatric Oncology Group study (now The Children's Oncology Group)

Beverly Bell(Children's Medical Center), Bruce M. Camitta(Medical College of Wisconsin), Jonathan J. Shuster(Health Outcomes Solutions (United States)), Bruce Bostrom(Minnesota West Community & Technical College), S. Sterikoff(Children's Medical Center), Gary R. Erdmann, G.N. Brockway(Children's Medical Center)
Pediatric Blood & Cancer
May 24, 2004
10.1002/pbc.20089
Cited by 29

Related Papers

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599
A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
|Blood|2006|475
Nutritional phases in Prader–Willi syndrome
|American Journal of Medical Genetics Part A|2011|432